<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02013388</url>
  </required_header>
  <id_info>
    <org_study_id>N91115-1H-01</org_study_id>
    <nct_id>NCT02013388</nct_id>
  </id_info>
  <brief_title>MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects</brief_title>
  <acronym>SNO2</acronym>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nivalis Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nivalis Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study in healthy subjects to assess the safety, tolerability, and pharmacokinetics of
      N91115.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 1 study in healthy subjects is being conducted to assess the safety, tolerability,
      and pharmacokinetics of N91115. Also, a comparison of the fasted versus fed with a high fat
      meal were compared for PK.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of N91115</measure>
    <time_frame>21 Days</time_frame>
    <description>Assessments are based on numbers of subjects with abnormal clinical evaluations, abnormal laboratory assessments, and adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Day 1 AUClast</measure>
    <time_frame>Day 1</time_frame>
    <description>Day 1 AUClast plasma values from treatment groups completing 14 days of N91115 administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: AUCtau Day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>Plasma analysis of AUCtau values from the end of the dosing period (Day 14) with N91115</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Day 1 Plasma Cmax Values</measure>
    <time_frame>Day 1</time_frame>
    <description>All subjects who completed sample collections for Day 1 plasma N91115</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Plasma Cmax Values on Day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>Plasma Cmax values from Day 14 subjects with repeat administration of N91115</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral daily dose of 10 mg N91115 for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single oral daily dose of placebo for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral daily dose of 50 mg N91115 for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg (single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral dose of 50 mg N91115</description>
  </arm_group>
  <arm_group>
    <arm_group_label>250 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral daily dose of 250 mg N91115 for 14 days (fasted)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>250 mg (Fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral daily dose of 250 mg N91115 for 1 day (fed fat meal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral daily dose of 500 mg N91115 for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Day 1 only</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single oral dose of placebo (Day 1 only)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N91115</intervention_name>
    <description>Given PO daily for 14 days</description>
    <arm_group_label>10 mg</arm_group_label>
    <arm_group_label>50 mg</arm_group_label>
    <arm_group_label>250 mg</arm_group_label>
    <arm_group_label>500 mg</arm_group_label>
    <other_name>Cavosonstat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given PO daily for 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N91115</intervention_name>
    <description>Given PO only on Day 1</description>
    <arm_group_label>50 mg (single dose)</arm_group_label>
    <arm_group_label>250 mg (Fed)</arm_group_label>
    <other_name>Cavosonstat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo-Day 1 only</intervention_name>
    <description>Given PO- only on Day 1 (single dosed to match single dose treatments)</description>
    <arm_group_label>Placebo-Day 1 only</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject voluntarily agrees to participate in this study and signs an Institutional
             Review Board (IRB)-approved informed consent prior to performing any of the screening
             procedures and in the opinion of the PI complies with all the requirements of the
             study.

          -  Subject is healthy, determined at the screening medical evaluation (including but not
             limited to medical history, physical examination and clinical laboratory evaluations).

          -  Subject is Caucasian.

          -  Female subject must be of non-childbearing potential (surgically sterile [hysterectomy
             or bilateral tubal ligation] or post-menopausal â‰¥ 1 year with follicle stimulating
             hormone [FSH] &gt; 40 U/L). Women receiving hormone replacement therapy (HRT) are
             eligible to enroll.

          -  Male subject must agree to use condoms and refrain from sperm donation from Day 1
             until 30 days post last dose or have documentation of vasectomy.

          -  Subject has a body weight &gt; 50 kg and body mass index (BMI) between 19.5 and 32 kg/m2,
             inclusive, at screening.

          -  Subject has no clinically significant abnormal findings related to their systolic or
             diastolic blood pressure (BP), per the investigator's judgment, at screening or Day 1.

          -  Subject has no clinically significant abnormal findings in 12 lead ECG, per the
             investigator's judgment, at screening.

        Exclusion Criteria:

          -  Subject has clinically significant history or evidence of cardiovascular, respiratory,
             hepatic, renal, gastrointestinal, endocrine, neurological, immunological, or
             psychiatric disorder(s) as determined by the investigator or designee.

          -  Subject has clinically significant abnormalities on a 12 lead ECG done at screening

          -  Subject has clinically significant abnormalities on a 48-hour ambulatory ECG done at
             screening

          -  Subject has any disorder that would interfere with the absorption, distribution,
             metabolism, or excretion of drugs.

          -  Subject has any concurrent disease or condition that, in the opinion of the
             investigator, would make the subject unsuitable for participation in the clinical
             study.

          -  Subject is unlikely to comply with the protocol requirements, instructions, and study
             related restrictions; e.g., uncooperative attitude, unavailable for follow-up call,
             and/or improbability of completing the clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Galloway, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Davita Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven A Shoemaker, MD</last_name>
    <role>Study Director</role>
    <affiliation>Nivalis Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://n30pharma.com</url>
    <description>Home Page</description>
  </link>
  <link>
    <url>http://davitaclinicalresearch.com</url>
    <description>Phase 1 Unit</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2013</study_first_submitted>
  <study_first_submitted_qc>December 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2013</study_first_posted>
  <results_first_submitted>March 5, 2015</results_first_submitted>
  <results_first_submitted_qc>March 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 18, 2015</results_first_posted>
  <last_update_submitted>November 3, 2016</last_update_submitted>
  <last_update_submitted_qc>November 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>N91115</keyword>
  <keyword>GSNORi</keyword>
  <keyword>SNO</keyword>
  <keyword>Cavosonstat</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>single oral daily dose of placebo for 14 days
Placebo: Given PO daily for 14 days</description>
        </group>
        <group group_id="P2">
          <title>10 mg</title>
          <description>single oral daily dose of 10 mg N91115 for 14 days
N91115: Given PO daily for 14 days</description>
        </group>
        <group group_id="P3">
          <title>50 mg</title>
          <description>single oral daily dose of 50 mg N91115 for 14 days
N91115: Given PO daily for 14 days</description>
        </group>
        <group group_id="P4">
          <title>250 mg</title>
          <description>single oral daily dose of 250 mg N91115 for 14 days (fasted)
N91115: Given PO daily for 14 days</description>
        </group>
        <group group_id="P5">
          <title>500 mg</title>
          <description>single oral daily dose of 500 mg N91115 for 14 days
N91115: Given PO daily for 14 days</description>
        </group>
        <group group_id="P6">
          <title>50 mg (Single Dose)</title>
          <description>single oral dose of 50 mg N91115
N91115: Given PO only on Day 1</description>
        </group>
        <group group_id="P7">
          <title>250 mg (Fed)</title>
          <description>single oral daily dose of 250 mg N91115 for 1 day (fed fat meal)
N91115: Given PO only on Day 1</description>
        </group>
        <group group_id="P8">
          <title>Placebo-single Dose</title>
          <description>Placebo: Given PO daily for 1 day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>work emergency</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>single oral daily dose of placebo for 14 days
Placebo: Given PO daily for 14 days</description>
        </group>
        <group group_id="B2">
          <title>10 mg</title>
          <description>single oral daily dose of 10 mg N91115 for 14 days
N91115: Given PO daily for 14 days</description>
        </group>
        <group group_id="B3">
          <title>50 mg</title>
          <description>single oral daily dose of 50 mg N91115 for 14 days
N91115: Given PO daily for 14 days</description>
        </group>
        <group group_id="B4">
          <title>250 mg</title>
          <description>single oral daily dose of 250 mg N91115 for 14 days (fasted)
N91115: Given PO daily for 14 days</description>
        </group>
        <group group_id="B5">
          <title>500 mg</title>
          <description>single oral daily dose of 500 mg N91115 for 14 days
N91115: Given PO daily for 14 days</description>
        </group>
        <group group_id="B6">
          <title>50 mg (Single Dose)</title>
          <description>single oral dose of 50 mg N91115
N91115: Given PO only on Day 1</description>
        </group>
        <group group_id="B7">
          <title>250 mg (Fed)</title>
          <description>single oral daily dose of 250 mg N91115 for 1 day (fed fat meal)
N91115: Given PO only on Day 1</description>
        </group>
        <group group_id="B8">
          <title>Placebo- Single Dose</title>
          <description>single oral dose Placebo: Given PO daily for 1day</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="4"/>
            <count group_id="B9" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.6" spread="12.32"/>
                    <measurement group_id="B2" value="41.3" spread="14.90"/>
                    <measurement group_id="B3" value="40.2" spread="14.25"/>
                    <measurement group_id="B4" value="39.7" spread="10.03"/>
                    <measurement group_id="B5" value="37.3" spread="10.91"/>
                    <measurement group_id="B6" value="42.3" spread="9.40"/>
                    <measurement group_id="B7" value="37.8" spread="11.84"/>
                    <measurement group_id="B8" value="41.3" spread="11.59"/>
                    <measurement group_id="B9" value="39.1" spread="11.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of N91115</title>
        <description>Assessments are based on numbers of subjects with abnormal clinical evaluations, abnormal laboratory assessments, and adverse events.</description>
        <time_frame>21 Days</time_frame>
        <population>All patients enrolled in the study were evaluated for safety endpoints</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>single oral daily dose of placebo for 14 days
Placebo: Given PO daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>10 mg</title>
            <description>single oral daily dose of 10 mg N91115 for 14 days
N91115: Given PO daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>50 mg</title>
            <description>single oral daily dose of 50 mg N91115 for 14 days
N91115: Given PO daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>250 mg</title>
            <description>single oral daily dose of 250 mg N91115 for 14 days (fasted)
N91115: Given PO daily for 14 days</description>
          </group>
          <group group_id="O5">
            <title>500 mg</title>
            <description>single oral daily dose of 500 mg N91115 for 14 days
N91115: Given PO daily for 14 days</description>
          </group>
          <group group_id="O6">
            <title>50 mg (Single Dose)</title>
            <description>single oral dose of 50 mg N91115
N91115: Given PO only on Day 1</description>
          </group>
          <group group_id="O7">
            <title>250 mg (Fed)</title>
            <description>single oral daily dose of 250 mg N91115 for 1 day (fed fat meal)
N91115: Given PO only on Day 1</description>
          </group>
          <group group_id="O8">
            <title>Placebo- Single Dose</title>
            <description>single oral dose Placebo: Given PO daily for 1day</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of N91115</title>
          <description>Assessments are based on numbers of subjects with abnormal clinical evaluations, abnormal laboratory assessments, and adverse events.</description>
          <population>All patients enrolled in the study were evaluated for safety endpoints</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with at least one TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with at least one study treatment TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Day 1 AUClast</title>
        <description>Day 1 AUClast plasma values from treatment groups completing 14 days of N91115 administration</description>
        <time_frame>Day 1</time_frame>
        <population>All patients that had plasma samples collected were included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg</title>
            <description>single oral daily dose of 10 mg N91115 for 14 days
N91115: Given PO daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>50 mg</title>
            <description>single oral daily dose of 50 mg N91115 for 14 days
N91115: Given PO daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>250 mg</title>
            <description>single oral daily dose of 250 mg N91115 for 14 days (fasted)
N91115: Given PO daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>500 mg</title>
            <description>single oral daily dose of 500 mg N91115 for 14 days
N91115: Given PO daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Day 1 AUClast</title>
          <description>Day 1 AUClast plasma values from treatment groups completing 14 days of N91115 administration</description>
          <population>All patients that had plasma samples collected were included in the analysis</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="327" spread="24.0"/>
                    <measurement group_id="O2" value="1530" spread="23.5"/>
                    <measurement group_id="O3" value="12000" spread="20.6"/>
                    <measurement group_id="O4" value="32400" spread="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: AUCtau Day 14</title>
        <description>Plasma analysis of AUCtau values from the end of the dosing period (Day 14) with N91115</description>
        <time_frame>Day 14</time_frame>
        <population>All patients that completed the required days of dosing to study end</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg</title>
            <description>single oral daily dose of 10 mg N91115 for 14 days
N91115: Given PO daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>50 mg</title>
            <description>single oral daily dose of 50 mg N91115 for 14 days
N91115: Given PO daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>250 mg</title>
            <description>single oral daily dose of 250 mg N91115 for 14 days (fasted)
N91115: Given PO daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>500 mg</title>
            <description>single oral daily dose of 500 mg N91115 for 14 days
N91115: Given PO daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: AUCtau Day 14</title>
          <description>Plasma analysis of AUCtau values from the end of the dosing period (Day 14) with N91115</description>
          <population>All patients that completed the required days of dosing to study end</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="423" spread="17.1"/>
                    <measurement group_id="O2" value="2240" spread="23.4"/>
                    <measurement group_id="O3" value="14500" spread="17.9"/>
                    <measurement group_id="O4" value="36000" spread="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Day 1 Plasma Cmax Values</title>
        <description>All subjects who completed sample collections for Day 1 plasma N91115</description>
        <time_frame>Day 1</time_frame>
        <population>All subjects that completed the plasma collection sampling were included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg</title>
            <description>single oral daily dose of 10 mg N91115 for 14 days
N91115: Given PO daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>50 mg</title>
            <description>single oral daily dose of 50 mg N91115 for 14 days
N91115: Given PO daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>250 mg</title>
            <description>single oral daily dose of 250 mg N91115 for 14 days (fasted)
N91115: Given PO daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>500 mg</title>
            <description>single oral daily dose of 500 mg N91115 for 14 days
N91115: Given PO daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Day 1 Plasma Cmax Values</title>
          <description>All subjects who completed sample collections for Day 1 plasma N91115</description>
          <population>All subjects that completed the plasma collection sampling were included in the analysis</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0" spread="32.2"/>
                    <measurement group_id="O2" value="245" spread="55.4"/>
                    <measurement group_id="O3" value="1810" spread="50.2"/>
                    <measurement group_id="O4" value="3840" spread="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Plasma Cmax Values on Day 14</title>
        <description>Plasma Cmax values from Day 14 subjects with repeat administration of N91115</description>
        <time_frame>Day 14</time_frame>
        <population>All subjects completing plasma collection sampling for N91115</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg</title>
            <description>single oral daily dose of 10 mg N91115 for 14 days
N91115: Given PO daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>50 mg</title>
            <description>single oral daily dose of 50 mg N91115 for 14 days
N91115: Given PO daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>250 mg</title>
            <description>single oral daily dose of 250 mg N91115 for 14 days (fasted)
N91115: Given PO daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>500 mg</title>
            <description>single oral daily dose of 500 mg N91115 for 14 days
N91115: Given PO daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Plasma Cmax Values on Day 14</title>
          <description>Plasma Cmax values from Day 14 subjects with repeat administration of N91115</description>
          <population>All subjects completing plasma collection sampling for N91115</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.3" spread="44.4"/>
                    <measurement group_id="O2" value="445" spread="48.6"/>
                    <measurement group_id="O3" value="2410" spread="30.3"/>
                    <measurement group_id="O4" value="5800" spread="67.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected from the time of informed consent for the study duration (up to 14 days) and during a non-dosing period of 7 days afterwards.</time_frame>
      <desc>Treatment emergent adverse event (TEAE), defined as AEs that are not present prior to the start of study medication, or present before study medication that worsened after starting study medication. TEAEs may be related to study or a procedure conducted during the study.
Subject is counted only once within System organ class and preferred term.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>single oral daily dose of placebo for 14 days
Placebo: Given PO daily for 14 days</description>
        </group>
        <group group_id="E2">
          <title>10 mg</title>
          <description>single oral daily dose of 10 mg N91115 for 14 days
N91115: Given PO daily for 14 days</description>
        </group>
        <group group_id="E3">
          <title>50 mg</title>
          <description>single oral daily dose of 50 mg N91115 for 14 days
N91115: Given PO daily for 14 days</description>
        </group>
        <group group_id="E4">
          <title>250 mg</title>
          <description>single oral daily dose of 250 mg N91115 for 14 days (fasted)
N91115: Given PO daily for 14 days</description>
        </group>
        <group group_id="E5">
          <title>500 mg</title>
          <description>single oral daily dose of 500 mg N91115 for 14 days
N91115: Given PO daily for 14 days</description>
        </group>
        <group group_id="E6">
          <title>50 mg (Single Dose)</title>
          <description>single oral dose of 50 mg N91115
N91115: Given PO only on Day 1</description>
        </group>
        <group group_id="E7">
          <title>250 mg (Fed)</title>
          <description>single oral daily dose of 250 mg N91115 for 1 day (fed fat meal)
N91115: Given PO only on Day 1</description>
        </group>
        <group group_id="E8">
          <title>Placebo- Single Dose</title>
          <description>single oral dose Placebo: Given PO daily for 1day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA, Version 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Ventricular Extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Eye Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aphthous Stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Change Of Bowel Habit</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Soft Tissue Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urine Odor Abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis Contact</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nivalis Therapeutics, Inc. (Formerly N30 Pharma)</name_or_title>
      <organization>Nivalis Therapeutics, Inc.</organization>
      <phone>720-945-7700</phone>
      <email>steven.shoemaker@nivalis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

